DDI-DrugBank.d602.s0 >> Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). >> 42-48,139-148
DDI-DrugBank.d602.s1 >> Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. >> 27-33,76-86
DDI-DrugBank.d602.s2 >> Caution is recommended when administering doxorubicin with NEXAVAR. >> 42-52,59-65
DDI-DrugBank.d602.s3 >> Sorafenib inhibits CYP2B6 and CYP2C8 in vitro with Ki values of 6 and 1-2 ?M, respectively. >> 0-8
DDI-DrugBank.d602.s4 >> Systemic exposure to substrates of CYP2B6 and CYP2C8 is expected to increase when co-administered with NEXAVAR. >> 103-109
DDI-DrugBank.d602.s5 >> Caution is recommended when administering substrates of CYP2B6 and CYP2C8 with NEXAVAR. >> 79-85
